Voloridge Investment Management
ARCT icon

Voloridge Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

Voloridge Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-57,486
Closed -$1.47M – 1151
2023
Q3 		$1.47M Buy
57,486
+15,479
+37% +$477K 0.01% 1012
2023
Q2 		$1.2M Buy
+42,007
New +$1.14M 0.01% 1083
2022
Q1 		– Sell
-31,396
Closed -$1.16M – 1351
2021
Q4 		$1.16M Sell
31,396
-16,765
-35% -$683K 0.01% 1236
2021
Q3 		$2.3M Sell
48,161
-168,762
-78% -$7.56M 0.01% 1004
2021
Q2 		$7.34M Sell
216,923
-71,956
-25% -$2.44M 0.05% 507
2021
Q1 		$11.9M Buy
288,879
+238,728
+476% +$14.2M 0.09% 300
2020
Q4 		$2.18M Buy
+50,151
New +$3.4M 0.02% 707

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Voloridge Investment Management's ARCT Position: Q4 2023 in Review

Voloridge Investment Management sold out of Arcturus Therapeutics (ARCT) in Q4 2023, closing a stake of 57,486 shares — an estimated $1.47M sold.

Voloridge Investment Management first reported a position in ARCT in Q4 2020 and held it in 7 quarters. The position peaked at $11.9M in Q1 2021. 165 funds tracked by Wall St. Rank hold ARCT as of Q4 2023.

  • Voloridge Investment Management reported no remaining Arcturus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 57,486 Arcturus Therapeutics shares in Q4 2023, an estimated $1.47M.
  • Voloridge Investment Management first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 7 quarters.
  • Voloridge Investment Management's Arcturus Therapeutics position peaked at $11.9M in Q1 2021.
  • 165 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2023.

Based on Voloridge Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.